An initiative in the LAL business to change from agency sales to direct sales in Europe and strengthen sales capabilities and the sales structure. It also includes expanded sales of in vitro diagnostic reagents for glucan measurement and a decline in overseas revenue following the infectious-disease-related demand surge.